Advertisement
U.S. Markets closed
S&P Futures
5,887.25 -5.25 (-0.09%) Dow Futures
43,049.00 -120.00 (-0.28%) Nasdaq Futures
20,515.00 -27.00 (-0.13%) Russell 2000 Futures
2,246.90 +0.70 (+0.03%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,760.50 +0.70 (+0.03%)
Almirall, S.A. (ALM.MC)
MCE - MCE Delayed Price. Currency in EUR
Follow
At close: 05:35PM CEST
| Previous Close | 9.20 |
| Open | 9.25 |
| Bid | 8.90 x 0 |
| Ask | 9.30 x 0 |
| Day's Range | 9.14 - 9.30 |
| 52 Week Range | 7.85 - 10.04 |
| Volume | |
| Avg. Volume | 108,292 |
| Market Cap | 1.974B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.19 |
| Earnings Date | Nov 11, 2024 |
| Forward Dividend & Yield | 0.18 (2.00%) |
| Ex-Dividend Date | May 17, 2024 |
| 1y Target Est | 13.48 |
Pharmaceutical TechnologyAlmirall completes EU regulatory procedure for antifungal Jublia
Onychomycosis is a serious fungal infection impacting an estimated 5.5% of the world's population.
Business WireAlmirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
BARCELONA, Spain, October 15, 2024--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful completion of the decentralized regulatory procedure in Europe for efinaconazole, a triazole antifungal compound indicated for the treatment of fungal infection of the nail, known as onychomycosis, under the trade name of Jublia®.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.